Creative Medical Technology Holdings (CELZ) Income from Continuing Operations (2010 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Income from Continuing Operations of 1403717.0 for Q1 2026, up 14.31% year-over-year from 1228012.2 in Q1 2025, and up 37.05% quarter-over-quarter from 2230048.0 in Q4 2025.
Creative Medical Technology Holdings (CELZ) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Income from Continuing Operations for 17 consecutive years, with 1403717.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 14.31% year-over-year to 1403717.0; the TTM figure through Mar 2026 stood at 6103002.0 (up 15.39% YoY), while the FY2025 annual figure was 6337382.0, up 4.21% from the prior year.
- Income from Continuing Operations improved to 1403717.0 in Q1 2026 per CELZ's latest filing, from 2230048.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 982339.0 in Q3 2022 and bottomed at 6215692.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 1752231.65 across 5 years, with a median of 1403717.0 in 2026.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 104.15% — and 2023, when it jumped 72.99%.
- Creative Medical Technology Holdings' Income from Continuing Operations stood at 6215692.0 in 2022, then surged by 72.99% to 1678574.0 in 2023, then tumbled by 77.34% to 2976814.0 in 2024, then climbed by 25.09% to 2230048.0 in 2025, then surged by 37.05% to 1403717.0 in 2026.
- Business Quant data shows CELZ's Income from Continuing Operations at 1403717.0 in Q1 2026, 2230048.0 in Q4 2025, and 1235934.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Creative Medical Technology Holdings | 1.88 Mn | 1.88 Mn | - | -1.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.51 Mn |
| Mar 31, 2026 | -1.40 Mn |
| Dec 31, 2025 | -2.23 Mn |
| Sep 30, 2025 | -1.24 Mn |
| Jun 30, 2025 | -1.23 Mn |
| Mar 31, 2025 | -1.64 Mn |
| Dec 31, 2024 | -2.98 Mn |
| Sep 30, 2024 | -1.04 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Mar 31, 2024 | -1.04 Mn |
| Dec 31, 2023 | -1.68 Mn |
| Sep 30, 2023 | -1.45 Mn |
| Jun 30, 2023 | -1.10 Mn |
| Mar 31, 2023 | -1.05 Mn |
| Dec 31, 2022 | -6.22 Mn |
| Sep 30, 2022 | -982,339.00 |
| Jun 30, 2022 | -1.79 Mn |
| Mar 31, 2022 | -1.15 Mn |
| Dec 31, 2021 | -3.88 Mn |
| Sep 30, 2021 | -1.84 Mn |